Axsome Therapeutics (AXSM) EBIAT (2022 - 2025)
Axsome Therapeutics (AXSM) has disclosed EBIAT for 4 consecutive years, with -$28.6 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 61.88% to -$28.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$183.2 million through Dec 2025, up 36.22% year-over-year, with the annual reading at -$183.2 million for FY2025, 36.22% up from the prior year.
- EBIAT hit -$28.6 million in Q4 2025 for Axsome Therapeutics, up from -$47.2 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$11.2 million in Q1 2023 to a low of -$98.7 million in Q4 2023.
- Historically, EBIAT has averaged -$56.0 million across 4 years, with a median of -$60.3 million in 2022.
- Biggest five-year swings in EBIAT: soared 71.69% in 2023 and later plummeted 509.35% in 2024.
- Year by year, EBIAT stood at -$61.2 million in 2022, then crashed by 61.09% to -$98.7 million in 2023, then increased by 24.06% to -$74.9 million in 2024, then skyrocketed by 61.88% to -$28.6 million in 2025.
- Business Quant data shows EBIAT for AXSM at -$28.6 million in Q4 2025, -$47.2 million in Q3 2025, and -$48.0 million in Q2 2025.